Amicus Therapeutics

FOLD · NASDAQ🇺🇸

Overview

Earnings Dividends Seasonality Metrics

Reported earnings about 1 month ago

Revenue Growth at CER

20%

Galafold Growth at CER

14%

Pombiliti + Opfolda Growth at CER

Loading...

Amicus Therapeutics

Unlock previous datapoints

Upgrade

Amicus Therapeutics

Unlock previous datapoints

Upgrade

Amicus Therapeutics Revenue by Segment

Revenue by Segment

Galafold Revenue

Unlock previous datapoints

Upgrade

CapyFin.com

Pombiliti + Opfolda Revenue

CapyFin.com

Historical Earnings Impact

Analyze how earnings announcements historically affect stock price performance

Avg. Return Before/After Earnings

Loading earnings performance data...

Loading earnings reaction data...

Key Statistics

Market Cap

$4.52B

P/E Ratio

68.83

Sector

N/A

Industry

N/A

52-Week High

$14.4

52-Week Low

$5.63

Revenue Growth at CER

20%

Galafold Growth at CER

14%

Pombiliti + Opfolda Growth at CER

51%

GAAP Operating Expenses

$143M

Non-GAAP Operating Expenses

$114M

Products

Get in Touch

Resources

Amicus Therapeutics

Amicus Therapeutics

Amicus Therapeutics

Amicus Therapeutics Revenue by Segment

Revenue by Segment

Galafold Revenue

Pombiliti + Opfolda Revenue

Historical Earnings Impact

Avg. Return Before/After Earnings

Key Statistics